TSBX · Insider Trading
Turnstone Biologics Corp. Common Stock
Every open-market purchase and sale reported by TSBX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-08-12 | OrbiMed Capital GP VI LLC | Director | U | −6,198,530 | — |
| 2025-08-12 | Versant Ventures V, LLC | 10%+ Owner | U | −33,816,920 | — |
| 2025-08-08 | Rishi Gupta | Director | U | −3,099,265 | — |
| 2025-08-08 | Davis Jerel | Director | U | −3,381,692 | — |
| 2024-07-02 | Kanya Rajangam | Director | A | +12,770 deriv. | — |
| 2024-07-02 | William D. Waddill | Director | A | +12,770 deriv. | — |
| 2024-07-02 | Robert J Gould | Director | A | +12,770 deriv. | — |
| 2024-07-02 | Davis Jerel | Director | A | +12,770 deriv. | — |
| 2024-07-02 | Rishi Gupta | Director | A | +12,770 deriv. | — |
| 2024-04-16 | William D. Waddill | Director | A | +25,540 deriv. | — |
| 2024-01-11 | FMR LLC | — | — | — | — |
| 2023-10-17 | Venkat Ramanan | Chief Financial Officer | A | +46,606 deriv. | — |
| 2023-10-17 | Rishi Gupta | Director | A | +25,540 deriv. | — |
| 2023-10-17 | Peter Joseph Campisi Jr. | Chief Legal Officer | A | +44,377 deriv. | — |
| 2023-10-17 | Stewart Abbot | Chief Scientific Officer | A | +45,542 deriv. | — |
| 2023-10-17 | Davis Jerel | Director | A | +25,540 deriv. | — |
| 2023-10-17 | Saryah Azmat | Chief Business Officer | A | +56,637 deriv. | — |
| 2023-10-17 | Michael F. Burgess | Interim Chief Medical Officer | A | +11,464 deriv. | — |
| 2023-10-17 | Sammy J. Farah | President & CEO | A | +155,321 deriv. | — |
| 2023-10-17 | Kanya Rajangam | Director | A | +8,012 deriv. | — |
| 2023-07-27 | FMR LLC | 10%+ Owner | C | +1,133,987 | — |
| 2023-07-27 | Davis Jerel | Director | MIXED | +3,381,692 | +$2.70M |
| 2023-07-27 | Versant Ventures V GP-GP (Canada), Inc. | 10%+ Owner | MIXED | +33,816,920 | +$27.00M |
| 2023-07-24 | ORBIMED ADVISORS LLC | Director | MIXED | +6,198,530 | +$10.00M |
| 2023-07-24 | Rishi Gupta | Director | MIXED | +3,099,265 | +$5.00M |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the TSBX quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.